169 -5 (79) 2025 - Yitmasova T.D., Teshaev Sh.Dj. - CLINICAL EFFICACY OF THIAZIDE IN THE TREATMENT OF MDR PULMONARY TUBERCULOSIS

CLINICAL EFFICACY OF THIAZIDE IN THE TREATMENT OF MDR PULMONARY TUBERCULOSIS

Yitmasova T.D. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Teshaev Sh.Dj. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Usmonov I.Kh. - Republican Specialized Scientific and Practical Medical Center of Phthisiology and Pulmonology

Resume

Thiotriazoline (trade name) is known under the international nonproprietary name (INN) as " morpholinium salt of thiazide acid" or simply " thiazotic acid". is a domestic drug with membrane-stabilizing, anti-ischemic, antioxidant and immunomodulatory effects. In clinical practice, it is known as a hepatoprotector and cardioprotector . Thiotriazoline activates the body's antioxidant systems and inhibits lipid peroxidation, improves energy metabolism in cells under hypoxic conditions. Previously, the anti-inflammatory and organoprotective effect of thiotriazoline in patients with tuberculosis was reported. These properties served as the basis for attempts to use thiotriazoline as a pathogenetic agent for pulmonary tuberculosis. It is expected that the addition of an antioxidant to therapy will increase the clinical effectiveness of treatment and reduce the incidence of complications.

Keywords: Thiotriazoline, hypoxia, granuloma, lung tissue, antioxidant.

First page

839

Last page

844

For citation:Yitmasova T.D., Teshaev Sh.Dj. Usmonov I.Kh. - CLINICAL EFFICACY OF THIAZIDE IN THE TREATMENT OF MDR PULMONARY TUBERCULOSIS//New Day in Medicine 5(79)2025 839-844 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. World Health Organization. Global tuberculosis report 2022. Geneva: WHO, 2022. 58 p.
2. Stop TB Partnership. The impact of the COVID-19 pandemic on TB response. Geneva: UNOPS, 2023.
3. Yunusov Sh.Sh. Modern trends of tuberculosis in the Republic of Uzbekistan // Vestn . phthisiology. - 2021. - No. 3. - P. 12-17.
4. Kurbatov S.A. Drug resistance of Mycobacterium tuberculosis: challenges of modern chemotherapy // Tuberculosis and lung diseases. - 2020. - Vol. 98, No. 6. - P. 7–13.
5. Levin A.S., Chernyshev V.I. Side effects of anti-tuberculosis drugs and ways of their correction // Clinical medicine. - 2019. - No. 12. - P. 22-26.
6. Golubev A.A., Kudryavtseva L.V. Hepatotoxicity in phthisiology: problems and solutions // Clinical pharmacology. - 2020. - V. 26, No. 2. - P. 48-52.
7. Blinova O.V. Modern aspects of pathogenetic therapy of tuberculosis // Med. science and education. Ural. - 2021. - No. 3. - P. 15-19.

   file

   download